The study focuses the dose administration of dabigatran to avoid the deaths due to hemorrhagic complications and thromboembolic stroke in clinics worldwide. To target the issue, a novel emerging acoustic technology, namely ''Quartz Crystal Microbalance with Dissipation'' (QCM-D) has been applied, while the acoustic assays namely ''activated Partial Thromboplastin Time'' (aPTT) and ''Prothrombinase complex-induced Clotting Test'' (PiCT) have been compared with the standard methods in parallel. Both techniques have been applied to 300 samples, including 220 plasma samples of patients suffering coagulation disorders and 80 plasma samples of non-patients. In comparison, the coagulation times of the acoustic aPTT and PiCT yielded an excellent correlation with the standard methods with in analytical standard deviation limits. Finally, the acoustic aPTT assay is the ''gold standard'' for a dose administration of the new oral anticoagulant, where the Δf/ΔΓ ratio of the acoustic assay demonstrates that dabigatran with FEIBA 50 combination could be a safe remedy to avoid the deaths in clinics.

这项研究集中了达比加群的剂量管理，以避免在全球各地的诊所中因出血并发症和血栓栓塞性中风而死亡。为了解决这个问题，已经应用了一种新兴的声学技术，即“具有消散作用的石英晶体微天平”（QCM-D），而声学测定法是“活化的部分凝血活酶时间”（aPTT）和“凝血酶原”复杂诱导凝血试验''（PiCT）已与标准方法平行进行了比较。两种技术均已应用于300个样本，包括220个患有凝血障碍的患者的血浆样本和80个非患者的血浆样本。相比下，声学aPTT和PiCT的凝结时间与标准方法的分析标准偏差极限之间具有极好的相关性。最后，声学aPTT分析是新口服抗凝剂剂量给药的“黄金标准”，其中声学分析的Δf/ΔΓ比值表明达比加群与FEIBA 50组合可以避免死亡的安全方法在诊所。